Bucks commissioners OK state award of $2 million for Pa. Biotechnology Center expansion – The Intelligencer

Posted on by

The Bucks County commissioners unanimously approved a $2 million state grant that will aid the expansion of the Pennsylvania Biotechnology Center in Buckingham.

With their vote Wednesday, the commissioners accepted the agreement between the biotechnology center and the state, and agreed to act as the facilitator for the Redevelopment Assistance Capital Program (RACP).

"Every entity that applies for the RACP grant has to have a cooperation agreement with one of the governments to move forward," said Lynn Bush, executive director of the Bucks County Planning Commission. "We are basically the go-between for the company and the state agency."

Plans have been in motion for years to add more laboratory and office space to the Biotechnology Center. The state grant and a $4.6 million federal grant will contribute to the overall costs of the project, estimated between $12 million and $13 million. The remainder willbe financed with a conventional loan awarded by Univest Bank.

"We're thrilled to continue our partnership with the biotechnology center and allow them the opportunity to grow and expand in that area," said Bucks County Commissioner Robert Loughery. "The center has become a real success story for the county and the region."

A groundbreaking ceremony for the expansion was held in April, but actual construction has yet to begin. Before work could begin in earnest, Bush said Thursday afternoon the plans need to go before the Buckingham Board of Supervisors for final land development approval.

The Biotechnology Center is credited with contributing approximately $1.8 billion to the local economy and supporting more than 700 jobs since its creation in 2007. A partnership with the Hepatitis B Foundation and Delaware Valley University started the initiative, but disagreements on the center's management ended the relationship.

The Hepatitis B Foundation bought out the university's interests in the center for $2 million in October, ending the disagreement and restarting the stalled expansion plans.

Go here to see the original:
Bucks commissioners OK state award of $2 million for Pa. Biotechnology Center expansion - The Intelligencer

Earnings Clues on Puma Biotechnology, Inc. (PBYI), AGNC Investment Corp. (AGNC) Analyst’s Predictions – StockNewsJournal

Posted on by

The Cerbat Gem
Earnings Clues on Puma Biotechnology, Inc. (PBYI), AGNC Investment Corp. (AGNC) Analyst's Predictions
StockNewsJournal
Investors who are keeping close eye on the stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) established that the company was able to keep return on investment at -163.88 in the trailing twelve month while Reuters data showed that industry's average ...
Puma Biotechnology Inc (PBYI) Upgraded at Cowen and CompanyThe Cerbat Gem
Puma Biotechnology, Inc. (NasdaqGS:PBYI): Honing in on the TechnicalsGeneva Journal
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other EventsMarket Exclusive
Chaffey Breeze -BBNS -Sports Perspectives -SEC.gov
all 41 news articles »

Go here to see the original:
Earnings Clues on Puma Biotechnology, Inc. (PBYI), AGNC Investment Corp. (AGNC) Analyst's Predictions - StockNewsJournal

Plandai Biotechnology Inc (PLPL) Shares Tick Down -7.52% – Morgan Research

Posted on by

Shares of Plandai Biotechnology Inc (PLPL) have been trending lowerover the past five bars, revealing bearishmomentum for the shares, as they ran -7.52% for the week. Looking further out we note that the shares have moved -5.38% over the past 4-weeks, -64.45% over the past half year and -38.50% over the past full year.

Plandai Biotechnology Inc (PLPL)s Williams Percent Range or 14 day Williams %R is currently at -77.00. In general, if the reading goes above -20, the stock may be considered to be overbought. Alternately, if the indicator goes under -80, this may show the stock as being oversold. The Williams Percent Range or Williams %R is a technical indicator that was developed to measure overbought and oversold market conditions. The Williams %R indicator helps show the relative situation of the current price close to the period being observed.

We can also take a look at the Average Directional Index or ADX of Plandai Biotechnology Inc (PLPL). The ADX is used to measure trend strength. ADX calculations are made based on the moving average price range expansion over a specified amount of time. ADX is charted as a line with values ranging from 0 to 100. The indicator is non-directional meaning that it gauges trend strength whether the stock price is trending higher or lower. The 14-day ADX presently sits at 54.95. In general, and ADX value from 0-25 would represent an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would indicate a very strong trend, and a value of 75-100 would signify an extremely strong trend. At the time of writing, the 14-day Commodity Channel Index (CCI) is -70.75. Developed by Donald Lambert, the CCI is a versatile tool that may be used to help spot an emerging trend or provide warning of extreme conditions. CCI generally measures the current price relative to the average price level over a specific time period. CCI is relatively high when prices are much higher than average, and relatively low when prices are much lower than the average.

A commonly used tool among technical stock analysts is the moving average. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. Moving averages can be very helpful for identifying peaks and troughs. They may also be used to assist the trader figure out proper support and resistance levels for the stock. Currently, the 200-day MA for Plandai Biotechnology Inc (PLPL) is sitting at 0.02. The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of stock price movements. The RSI was developed by J. Welles Wilder, and it oscillates between 0 and 100. Generally, the RSI is considered to be oversold when it falls below 30 and overbought when it heads above 70. RSI can be used to detect general trends as well as finding divergences and failure swings. The 14-day RSI is presently standing at 41.93, the 7-day is 36.38, and the 3-day is resting at 20.94.

Read this article:
Plandai Biotechnology Inc (PLPL) Shares Tick Down -7.52% - Morgan Research

ChineseInvestors.com Launches XiBiDi Biotechnology to Reach … – Yahoo Finance

Posted on by

SAN GABRIEL, California, March 20, 2017 /PRNewswire/ --

ChineseInvestors.com (CIIX) ('CIIX' or the 'Company'), the premier financial information website for Chinese-speaking investors, today announces that it has established and registered XiBiDi Biotechnology Co., Ltd. in the Pudong Free-Trade Area in Shanghai, with registered capital requirements of $1.45 million USD over the next 10 years. XiBiDi Biotechnology will focus on the online and offline sales of health products including hemp-derived CBD (cannabidiol) oil, as well as hemp-based food and beverages. Notably, the Chinese character 'XiBiDi' is homophonic to 'CBD' in English.

"I am delighted about the establishment and registration of our new hemp company," says CIIX founder and CEO, Warren Wang. "XiBiDi Biotechnology is strategically located in the Pudong Free-Trade Area of Shanghai, China, where we have the opportunity to reach a consumer base of nearly 1.4 billion people. We believe that this large population affords XiBiDi an outstanding opportunity to be the provider of choice for natural hemp products."

XiBiDi Biotechnology will be the operator of CIIX's recently launched CBD online store, http://www.ChineseCBDoil.com, which will primarily focus on selling, where legal, hemp-based CBD nutrient and health products to Chinese-speaking customers worldwide through the online retail process. CIIX is also in preparations to open a retail store based in the predominantly Chinese community of San Gabriel, California.

The establishment of XiBiDi Biotechnology supplements these ventures as well as the company's broader mission to develop its presence in the hemp industry. In addition to retail and direct sales, the company will focus on the legal import of hemp-based (but not CBD oil products) health products in China - a population increasingly interested in the health benefits of hemp and CBD oil - and the export of hemp food and beverages to the United States, Canada and Europe.

"As the aging population in China increases, Chinese people are paying more attention to their health; thus, we believe that the development of the health industry has a very bright future. CIIX is very excited to be the world's first U.S. publicly traded company promoting hemp-based CBD health products and hemp foods that will help Chinese people improve their overall health. In addition, being located in the Pudong Free-Trade Area provides great convenience for the company's future import and export business as China enacts various measures to support the development of the Pudong Free-Trade Area," concludes Wang.

XiBiDi Biotechnology is registered as a wholly foreign enterprise and the registration is expected to be completed by the end of March.

About ChineseInvestors.com (CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational-related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based CBD health products via its new website: http://www.ChineseCBDoil.com.

For more information visit http://www.ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds:https://www.facebook.com/Chinesefncom

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-looking Statement

Our discussion may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-K and Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading 'Risk Factors'.

Contact: ChineseInvestors.com, Inc. 227 W. Valley Blvd, #208 A, San Gabriel, CA 91776

Investor Relations: Alan Klitenic +1-214-636-2548

Corporate Communications: NetworkNewsWire (NNW) New York, New York http://www.NetworkNewsWire.com 212-418-1217 Office Editor@NetworkNewsWire.com

Read this article:
ChineseInvestors.com Launches XiBiDi Biotechnology to Reach ... - Yahoo Finance

BIO Statement on the Passing of Biotechnology Giant Henri Termeer … – Business Wire (press release)

Posted on by

WASHINGTON--(BUSINESS WIRE)--Henri Termeer, who passed away at the age of 71, was a founding father of modern biotechnology. He brought to his work, and to his life, a passion, a vision and a perseverance to bring ground-breaking medical innovations to those suffering from rare diseases.

Through his work, Termeer became a mentor and a role model for biotechnology entrepreneurs around the globe. The culture he created at Genzyme, and at the various institutions he worked for throughout his career, was widely seen as the gold standard for patient-focused drug development. He was a master at creating cultures where great science and great people could flourish. As the Boston Globe aptly noted, Termeer had magnetism and warmth, and a deft ability to harness top talent toward a common goal.

Termeer, who was a larger-than-life figure across the biotechnology field, was instrumental in the founding of BIO in 1993, serving as its first vice chair for health. He was named Chairman of the organization in 1996. During his tenure as Chair of BIO, and in the years that followed, Termeer was a key catalyst in the growth of the organization and in establishing BIOs position at the forefront of key policy and regulatory debates. He was an active member of BIOs Board of Directors since its founding until his death, with only a short break in his tenure. Termeer served on BIOs Executive Committee from 1993 to 2000.

Following are statements from leadership at the Biotechnology Innovation Organization (BIO):

Few people in our industry have had as profound an impact as Henri Termeer on the science of biotechnology and the patients who depend on it, said Jim Greenwood, President and CEO of BIO. He had a unique ability to inspire the men and women around him. Henri certainly was a brilliant businessman and a charismatic leader, but his burning passion was to do the unthinkable to innovate and to treat and cure rare diseases that others believed too difficult to tackle. Henri's love of his profession and the people in it was contagious. He taught us that even though our companies were sometimes competitors, our industry must speak with a united voice in the corridors of power. He was a founding father of BIO and thus the thriving ecosystem the biotechnology community enjoys today is another central part of his legacy. Henri was admired, respected and loved by all of us who were fortunate enough to know him as a colleague, a teacher, and a friend. He is an irreplaceable talent who will be long remembered and sorely missed.

Henri Termeer was a giant, said Ron Cohen, President & CEO of Acorda Therapeutics and Chair of BIO. He has left us much too soon. High among his many legacies are the tens of thousands of patients and their families who have benefited from Genzymes innovations, and the scores of biotechnology professionals whom he mentored and who have gone on to be leaders at other companies.

I had the honor of having worked at Genzyme and calling Henri Termeer amentor, said Paul Hastings, Chairman and CEO of OncoMed Pharmaceuticals and Vice Chair of BIO. He taught us all to be tough and business minded, while simultaneously taking into account how every decision impacted every person in the organization that was part of making Genzyme what it was. His focus on always doing the right thing for people and the business was something truly special. We all lost a great friend, a great mentor and awonderful role model.

From 1993-1998, Hastings served as Vice President, Global Marketing, Genzyme Therapeutics, President of Genzyme Europe and President of Genzyme Therapeutics.

"Henri has left us far too soon, but his legacy and contributions to our industry and patients with rare diseases will last forever, said John Maraganore, CEO of Alnylam Pharmaceuticals. Indeed, Henri pioneered the advancement of innovative medicines for orphan disease and inspired other companies and entrepreneurs to follow. He will be deeply missed."

"As an industry leader Henri was unparalleled and unrivaled, said Jeremy Levin, chairman and CEO of Ovid Therapeutics. As a mentor and friend, he was a foundational component of my business philosophy and career. He will be mourned and deeply missed but never forgotten."

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events

See the original post here:
BIO Statement on the Passing of Biotechnology Giant Henri Termeer ... - Business Wire (press release)

Why Should Investors Consider An Allocation In Speculative Biotechnology: A Sector Analysis – Seeking Alpha

Posted on by

Many intriguing articles have been written about investing in biotechnology. Biotechnology investment has been referenced by many knowledgeable and respectable authors as controversial, out of favor, and even sexy (this article by Stephen Simpson, CFA, is must read). Surviving current trends in biotechnology stock price manipulation can be both stressful and disappointing. This leaves us all to wonder is it even worth it to try speculative biotechnology as an investment option?

StrongBio believes it is worth it, even if it results in losses that are hard to endure. In the end, contributions to healthcare from growing sources of capital are extremely important for improved patient care (termed supply-side capital). As these contributions have grown, however, so too has waste. With proper selection, timing, and diversification (three pillars of biotechnology investment), the common retail investor can eventually be financially rewarded as philanthropic goals of the population are met.

Simply put, biotechnology companies focus on drug development aiming to treat an unmet or under-met disease or medical condition. Companies that have succeeded have net sales in the tens of billions and total market values in the hundreds of billions of dollars. Speculative biotechnology companies, in contrast, differ from proven top biotechnology companies in that they often have no approved products or revenues.

Gary Pisano of Harvard Business School has done extensive modeling of biotechnology (and other technology) returns. Reports between 2006 and 2012 indicate that average biotechnology returns have been historically unimpressive; with 25-year returns of "market baskets" of biotech stocks yielding only about 10% per year. This means that much of the legendary "opportunity" in biotechnology stocks revolves around successful portfolio management of technological trend shifts and timing positions accordingly.

Much of the challenges lie in the fact that science experts tend to focus into niches instead of pursue interdisciplinary science. Scientists tend to lack fundamental economics or business expertise and vice-versa, with business leaders lacking science background.

So what if a speculative biotechnology company has shown positive data in a curative treatment for cancer? Many things can still go wrong for an investor. One should always have a plan for setbacks and delays. Sometimes clinical setbacks can occur requiring a company to delay a trial until regulatory requirements are met. Other delays are more business-oriented, with slated clinical trials held up due to lack of funding such as in poor economic times.

Even legal setbacks occur and can cost both time and money. And then we have the gatekeeper: FDA, and regulatory setbacks that can occur. The fact is most biotechnology projects fail. According to Pisano, the average biotechnology company is likely to fail 90% of the time, with companies that make it all the way to Phase 3 experiencing approximately 50% chance of success.

Multidisciplinary investment management increases the likelihood of a success, meaning, that many common retail investors are going to have to try to wear multiple hats when performing qualitative analyses. That's what StrongBio calls work. It's a lot of work. But knowing what to look for in each discipline can be of great service to the retail investor.

And if all of those pitfalls are not enough, going back to our legitimate cancer data success scenario, market manipulation and fake news from negative press can still make investors feel like their winners are losing investments for quite some time. Take for instance the 2016 situation with Celator Pharmaceuticals, which was driven down to $0.79 cents per share and rose 1600% when whatever market forces that were holding it down, along with negative press, finally gave up the fight to an obvious winner (having been bought out by Jazz Pharmaceuticals (NASDAQ:JAZZ).

The oppressive forces on the stock persisted right up until FDA review. Other company shareholders, like those of Northwest Biotherapeutics (NASDAQ:NWBO), allege that negative press and stock manipulation are linked. Immunomedics's (NASDAQ:IMMU) stock see-sawed back and forth several times between $2 and $5 (and even drew a halt from the SEC), market cap between 180 million and 500 million respectfully, in 2016 with alternating negative legal press by no less than 20 law firms and positive research press and stock price volatility. Extreme patience is required while waiting for "fair value."

The University of Chicago oncologist Mark Ratain postulated that a company with a market cap of less than $300 million is unlikely to succeed. Commonly known in biotechnology investment circles, the Feuerstein-Ratain rule, was a solid predictor in the past. This year companies are defying the 300 million rule. StrongBio believes the rule used to hold water because there was a predictable method to the involvement of big pharma in purchasing speculative biotechnology cancer stocks.

So either big pharma is no longer able to identify useful technologies and many are slipping through the cracks, which is unlikely, or something in the markets is changing. It is also possible that it was getting predictable to pick biotechnology successes based upon the highly successful metric by the well-respected Feuerstein and Ratain, so market makers have changed it up a little. Past open market buyout periods of obtaining shares of speculative stocks drove prices up as a whole (or held them flat for long periods of time) to approximately 300 million market caps. Accumulation such as this no longer seems to be in effect.

Whatever the mechanism of value assignment by the market, it is clear there is a new market pattern emerging in biotechnology, with lower than normal market caps. StrongBio believes there may be several contributing reasons for this. One, investment levels are predicted to be the lowest that they have been since 1947. This is also true in the investment banking sector, a big source of biotechnology funding.

Simply put we have not had a great investment economy, and risky biotechnology may be regarded as an irresponsible investment during tough financial times. Because new patterns on speculative biotechnology company stocks show suppression over periods of months and years, it is possible there just is not as much retail and/or institutional support as in years past.

Two, is the SEC unconscious at the wheel or did someone outsource that job to Asia? This query addresses concern over foreign-based or hostile entities' ability to starve funding for cash hungry technology companies when they need to sell stock. In recent years, an increase in foreign companies cheaply acquiring U.S. biotechnologies developed at tax-payer-supported universities and other technologies funded by state and local governments has plagued markets.

New stock exchanges like IEX have even been set up in an attempt to thwart different kinds of financial manipulation utilizing delays in trade execution (read this book or a synopsis about it in Flash Boys; it's fascinating). However, the market is currently responding to new executive political leadership in a corrective way. One can always hope that a nation of laws will have proper enforcement.

Three, short sellers have influenced stock prices (being respectful of regulations) for a long time, but not to the extent that manipulation is occurring now. Foreign countries like those in Western Europe, Australia and Canada have entirely outlawed the practice of shorting on their own stock exchanges. This indicates these countries have identified that stocks were oversold and manipulated and regulations and laws limiting short sales were not able to control it.

It would appear pretty obvious to those following speculative biotechnology that the same is occurring in the U.S. For instance, one exploring and mining company presented evidence to the SEC of a naked short position in the hundreds of billions of shares. Regardless of mechanism there may be a way to estimate increases in short-selling using well established metrics in biotechnology.

StrongBio cites the 2016 failures (and likely more in 2017) of the long-established Feuerstein-Ratain rule as evidence NOT that the metric is somehow flawed, but rather that market conditions have changed. The 300 million "rule" is now as dated as 4-inch tile countertops for kitchens and bathrooms, and has likely been rendered obsolete by rampant stock price manipulation. But that does not mean that one should abandon biotechnology investments.

Eventually, a fair value is decided between a suitor and company management if something in the pipeline passes FDA and can be sold. Since Celator (NASDAQ:CPXX) rendered the Feuerstein-Ratain rule obsolete at a market cap of less than $100 million, and Immunomedics obtained FDA breakthrough therapy status in triple negative breast cancer at about $160 million, we know the static threshold value of 300 million is no longer even close to critical mass for the metric.

Out of fairness, the metric can be influenced by other factors such as a changing FDA landscape as well, but that wouldn't explain the difference in market cap as the FDA does not participate in stock pricing or market making per se. It follows that if market regulation returns to prior levels, the metric threshold would increase back to 300 million.

How much lower can the Feuerstein-Ratain critical threshold go? That may depend in part how many shares can be shorted in a given company. StrongBio cites here mention of a gnarly cancer drug company from a recent article by an author of the metric that has approvable Phase 3 data. According to a report by H.C. Wainright, this 40 million market cap company, CytRx (NASDAQ:CYTR), is likely to get some kind of approval pathway for aldoxorubicin on its statistically significant Phase 3 sarcoma data, where it outperformed all 5 other drugs in the study.

One might approximate that if short selling is the cause for lower market cap FDA approvals in cancer, estimates based upon how much additional share supply exists now versus when the rule was working can be made. 300 million, the past metric threshold, divided by 40 million, the current potential low, gives a WHOPPING 7.5-fold more potential share supply (provided to the market by short selling). This assumes that the relationship between stock price and shorting of shares has some kind of linear and direct relationship, such as common economic supply and demand curves.

This implies the Feuerstein-Ratain metric tool is a dynamic sliding-threshold subject to changing market factors. One might argue that a linear relationship would be less representative for a "real world" sigmoidal supply and demand model, such as that proposed by Alfred Marshall. These curves break from a linear path to form a smooth parabolic curve with sigmoid limits because of factors such as wear and tear of production equipment, transportation limits, and other practical factors in supply-side analysis. In an electronic market system of a thinly traded biotechnology stock, it is unlikely these factors are relevant.

This emerging scenario creates an even greater margin for profit if one can properly select stocks that are at a record low market cap threshold for FDA approval in cancer, sometimes called short squeeze. At some point, speculative biotechnology companies get a fair value assigned if management is honest enough to serve their fiduciary duty to shareholders. It is at the point of buyout that fair value was reached for CPXX. Fair value soon will be reached for IMMU based upon significant partnership (Seattle Genetics, SGEN) and possibly even CYTR.

StrongBio cautions the reader that CytRx has been accused of hiring stock promotion media in the past, and its pillar of honor might have been "pierced." Nonetheless it appears that after a substantial period of risk everything that was promoted is likely to be true. In addition, remember that biotechnology investment in a "market basket" of companies typically returns about 10%. StrongBio does not recommend deviating from this basket approach, but rather by changing weighting late into development and after dilutions, obtain higher than 10% returns when possible.

The primary pillar of biotechnology stock investing, selection, is obviously a critical factor, standing tall in front of the pillar of timing. How can we avoid picking a loser? The second pillar of timing comes down to choosing a company with favorable Phase 3 data as they meet with FDA in a type B meeting (where FDA reviews the data outcomes of a clinical study) and an abnormally low stock price compared to the annual market its product will serve.

These two pillars stand in synergism, as one doesn't have a favorable investment with only one solid pillar supporting a portfolio candidate under current market conditions. It is important to invest lightly at first so that lower prices do not cause harm to a portfolio. If the stock runs up just be happy you had a little.

The pitfall of regulatory hurdles is always a major concern, but there is circumstantial evidence that the FDA will be easing some burdens. Cancer drug shortages (such as existed for doxorubicin in December 2016) can be thwarted by increasing the number of suppliers and approving safer more effective derivatives. The FDA may favor competition to lower prices of potentially egregious monopolies. Cancer treatment in the hospital environment is currently trending towards increasing physician options and information as well as for patient-physician interaction as well.

For instance, some drugs may be hard on the liver and not be good for alcoholics, whereas other drugs may be rough on the heart, and be contra-indicated for heart attack sufferers. So demonstration of comparable efficacy may be acceptable if safety is improved for subsets of patients. Whether the desire for increased options will spread from cancer to other indications remains to be seen.

However it is no secret that Trump intends to "slash restraints" artificially put on drug makers by the FDA. If these trends come to fruition, StrongBio expects the chance of success of biotechnology companies to increase, but the markets for some drugs may sink into smaller niches of sales with greater total options available.

So there are certainly the same past investment risks that the FDA will not view data as favorable or that companies will have a hard time proving they can meet production standards for NDA approval, including lot to lot consistency. Oftentimes a speculative biotechnology company can partner this production with a number of firms.

But the reward to risk ratio can at least be dynamically tuned for investment success. With proper selection, timing, and diversification, StrongBio estimates that new regulatory policies and market conditions will make biotechnology investment potentially more common and successful as the outdated thresholds of the past are readjusted to guide investors.

Disclosure: I am/we are long IMMU CYTR.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

The rest is here:
Why Should Investors Consider An Allocation In Speculative Biotechnology: A Sector Analysis - Seeking Alpha

College hires leader for Biotechnology Center of Excellence – Triad Business Journal

Posted on by

Triad Business Journal
College hires leader for Biotechnology Center of Excellence
Triad Business Journal
Our Biotechnology Center of Excellence will be key to Alamance County's economic development and we are excited to have an administrator with the depth and breadth of experience as Yonnie Butler, said President Algie Gatewood. His range of ...

Go here to see the original:
College hires leader for Biotechnology Center of Excellence - Triad Business Journal

Ceramics artist inspired by nature, biotechnology – Jewish News of Greater Phoenix

Posted on by

Ceramist Susan Beiners work has been exhibited in China, France, the Netherlands and across the nation, but it took some persuading to get her to exhibit her creations at Temple Solels latest Art Showcase.

After some cajoling, Beiner relented and now her earlier work is on display at Temple Solel through May 31. A reception and talk featuring Beiner are scheduled for 10:30 a.m. Sunday, April 2, at Temple Solel, 6805 E. McDonald Drive, Paradise Valley.

Your current subscription does not provide access to this content. Please click the button below to manage your account.

kAmp %6>A=6 $@=6= >6>36C D:?46 a_`b[ q6:?6C 😀 2? 2DD@4:2E6 AC@76DD@C 2E pC:K@?2 $E2E6 &?:G6CD:EJD[ w6C36C86C r@==686 @7 u:?6 pCE] w6C 96D:E2?4J E@ D9@H 96C H@C< 2E $@=6= 42>6 7C@> E96 724ED E92E D96 925 ?6G6C 4@?D:56C65 5:DA=2J:?8 96C 2CE 😕 2 DJ?28@8F6 367@C6[ 2D H6== 2D E96 =2C86 D:K6 @7 96C =2E6DE 4C62E:@?D]k^Am

kAm(6 E@=5 $FD2? D96 H2D 2 EC6>6?5@FD C6D@FC46 2?5 2 A2CE @7 E96 E6>A=6 2?5 H6 H2?E65 E@ D66 96C H@C<[ D2:5 xC2 %9@>2D[ 2 >6>36C @7 E96 pCE o $@=6= 4@>>:EE66] %9:D 😀 E96 7:CDE E:>6 H6G6 925 2 46C2>:4:DE]k^Am

kAmx?DA:C65 3J E96 4C27ED >@G6>6?E[ q6:?6C 3682? 4C62E:?8 9:89=J 56E2:=65[ 2?5 2E E:>6D H9:>D:42=[ E62A@ED 😕 E96 62C=J `hh_D] p=E9@F89 D96 DE:== E@@< AC:56 :? 96C E62A@ED[ 3J a__b[ q6:?6C D2:5 D96 ?66565 2 8C62E6C 2CE:DE:4 492==6?86 2?5 >@G65 @? E@ =2C86 H2== :?DE2==2E:@?D 2?5 D4F=AEFC6D]k^Am

kAmx ;FDE 5:5?E H2?E E@ >2<6 E62A@ED 2?J>@C6[ q6:?6C D2:5] x 5:5?E 766= 2D E9@F89 E96 E62A@ED H6C6 23@FE E96 7F?4E:@?2= AC@5F4E 😕 2?J H2J] x E9:?< E96J H6C6 >@C6 23@FE 2 7@C> H:E9 H9:49 E@ >2<6 >@C6 D4F=AEFC2= @C:6?E2E:@?] p7E6C x 5:5 >J 7:CDE =2C86 H2== A:646 😕 a__b[ x 76=E x 4@F=5 8@ 7FCE96C] x 4@?D:56C E96 E62A@ED 😕 2 5:776C6?E H2J E92? x 5@ >J =2E6DE H@C<] ,%96 ?6H H@C<. :D 2 5:776C6?E >:?5D6E @7 9@H x> >2<:?8 :E[ H9J x> >2<:?8 :E 2?5 E96 :562D 369:?5 :E]k^Am

kAm%96 E9:?8D x >2<6 ?@H E2<6 2 =@E =@?86C[ 3FE E96J 2C6 >@C6 @7 2 492==6?86 2?5 x E9:?< E96J 86E 36EE6C 2?5 36EE6C H:E9 E:>6[ q6:?6C 25565] x =62C? 7C@> 6249 @?6 2?5 E@ >6 E92E 😀 H@CE9 6G6CJE9:?8]k^Am

kAm{:<6 96C E62A@ED[ 96C ?6H H@C2E6C:2=D DF49 2D A=6I:8=2DD[ 7@2> 2?5 24CJ=:4D] uC@> 272C[ E96 C6DF=ED 42? =@@< =:<6 2 82C56? @7 7=@H6CD F?E:= 4=@D6C 6I2>:?2E:@? C6G62=D E96 >2?>256[ :?5FDEC:2= 2CE:7:46 E92E C6AC6D6?ED 96C :?E6C6DE 😕 ?2EFC6 2?5 3:@E649?@=@8J]k^Am

kAm*@F 42?E E6== H92ED C62= 2?5 H92ED >256 2?J>@C6[ q6:?6C D2:5] (6 42? 8C@H 2?JE9:?8 😕 E6C>D @7 v|~D W86?6E:42==J >@5:7:65 @C82?:D>DX 2?5 E9:?8D =:<6 E92E] *@F 42? 8C@H 2?J A=2?E E@ 36 D@>6E9:?8 6=D6] %96C6 2C6 2== D@CED @7 E9:?8D E92E 2C6 36:?8 5@?6 E92E >2<6 >J H@C< D66> >@C6 C62=]k^Am

kAmsF6 E@ DA246 =:>:E2E:@?D 2E %6>A=6 $@=6=[ q6:?6C 😀 >@DE=J 6I9:3:E:?8 96C 62C=J E62A@ED]k^Am

kAmq6:?6C 😀 A2CE @7 E96 E9:C5 42==E@2CE:DED 7@C E96 pCE $9@H42D6 D6C:6D 2E %6>A=6 $@=6= D:?46 a_`a] $96 😀 ;@:?65 3J D6G6? @E96C 2CE:DED H@C<:?8 :? DF49 >65:F>D 2D 24CJ=:4D[ @:=[ A9@E@8C2A9J 2?5 A2:?E:?8] %96 2CE:DED H@C< 42? 2=D@ 36 AFC492D65[ H:E9 2 A6C46?E286 @7 E96 AC@4665D 8@:?8 E@ 7F?5 2? 2CE D49@=2CD9:A 2H2C565 2??F2==J E@ 2 E6>A=6 >6>36C 9:89 D49@@= D6?:@C]k^Am

kAm(6G6 366? C62==J 3=6DD65 92G:?8 D@ >2?J %6>A=6 $@=6= >6>36CD H:E9 D@ >2?J 5:G6CD6 <:?5D @7 E2=6?ED E2=6?ED E92E D@>6 @7 E96> 5@?E 6G6? C64@8?:K6 E96>D6=G6D[ %9@>2D D2:5] |6>36CD @7 @E96C DJ?28@8F6D 92G6 G:D:E65 %6>A=6 $@=6= E@ D66 E96 G2C:@FD pCE $9@H42D6D] %9@>2D 9@A6D E92E :?E6C6DE H:== 3=@DD@> :?E@ D@>6E9:?8 3:886C]k^Am

kAm(6C6 C62==J 9@A:?8 E92E 5@H? E96 C@25 H6 42? 86E 2? 2CE 4@>>F?:EJ H:E9:? E96 #67@C> 4@?8C682E:@?D 😕 E96 '2==6J[ 96 D2:5]k^Am

Janet Perez is a freelance writer based in Phoenix.

The rest is here:
Ceramics artist inspired by nature, biotechnology - Jewish News of Greater Phoenix

Area high schools to offer dual credit biotechnology courses through Ivy Tech – Greene County Daily World

Posted on by

Several area high schools will start offering students the opportunity to take dual credit courses through Ivy Tech and earn free college credit this spring.

Last fall, Ivy Tech Community College Bloomington was awarded a Perkins Competitive Grant from the Indiana Department of Education, worth $85,000, to increase rural career and technical education pathways in biotechnology, according to Cook Medical Content Specialist, Moriah Sowders.

The course will be available to students attending Brown County, Owen Valley, Eastern Greene and Bloomfield high schools.

Currently, the courses are taught by an Ivy Tech instructor, though the grant will also provide training for high school science teachers to begin teaching the course in the 2017-18 school year.

In an article previously published by the Greene County Daily World, Bloomfield Jr./Sr. High School announced it would begin piloting two courses, BIOT (biotechnology) 102, the survey of good manufacturing practices, in the fall semester beginning on Jan. 17, and BIOT 100, the survey of biotechnology in the spring semester.

Eastern Greene Principal Doug Lewis said a course began there in mid January and has been going well.

It helps prepare them for going into that field, they can get a leg up going into other classes or straight into the workforce, said Lewis.

Currently, Lewis said the course is taught by an instructor from Ivy Tech once a week, and the students also login online daily for course work. The course will be offered by an Eastern Greene teacher next semester, according to Lewis.

Cook Pharmica also provided an additional $15,000 to Ivy Tech Bloomington to help launch and sustain the program in the future by providing funding for textbooks which can then be reused by participating high schools.

We have a mission at Ivy Tech Bloomington to help fill the local industry skills gap, and one way we do that is through partnerships like this with Cook Pharmica, said Jennie Vaughan, chancellor at Ivy Tech Bloomington. With the help of this grant, high school students can take dual credit classes in biotechnology, developing a clear pathway toward employment in the life sciences, an industry thats thriving in our region.

Tedd Green, president of Cook Pharmica said, We appreciate the work Ivy Tech does to help students in the local community develop the skills they need to enter the workforce upon graduating high school. This program is a true community partnership that supports the education of our local youth and the workforce development needs of the growing life sciences industry in South Central Indiana. We are pleased to be a partner in this program.

According to Sowders, Cook Pharmica has grown to 715 employees and introduced its new My Cook Pathway education assistance program in 2016, which provides employees the opportunity to continue their education at no cost to them from day one when with the company.

To find out more information about Cook Pharmica visit http://www.cookpharmica.com or to find out more information about Ivy Tech Community College visit http://www.ivytech.edu

Go here to read the rest:
Area high schools to offer dual credit biotechnology courses through Ivy Tech - Greene County Daily World

Federal agencies need to prepare for greater quantity, range of … – Medical Xpress

Posted on by

March 9, 2017

A profusion of biotechnology products is expected over the next five to 10 years, and the number and diversity of new products has the potential to overwhelm the U.S. regulatory system, says a new report from the National Academies of Sciences, Engineering, and Medicine. The U.S. Environmental Protection Agency, the Food and Drug Administration, the U.S. Department of Agriculture, and other agencies involved in regulating biotechnology products should increase their scientific capabilities, tools, and expertise in key areas of expected growth, said the committee that conducted the study and wrote the report.

"The rate at which biotechnology products are introducedand the types of productsare expected to significantly increase in the next five to 10 years, and federal agencies need to prepare for this growth," said committee chair Richard Murray, Thomas E. and Doris Everhart Professor of Control and Dynamical Systems and Bioengineering, California Institute of Technology. "We hope this report will support agency efforts to effectively evaluate these future products in ways that ensure public safety, protect the environment, build public confidence, and support innovation."

The U.S. biotechnology economy is growing rapidly, with the scale, scope, and complexity of products increasing. More types of organisms will likely be engineered, the report notes, and the kinds of traits introduced with biotechnology will also increase. Some future biotechnology products are likely to use genome-editing techniques such as CRISPR for familiar applications, such as modifying agricultural crops. Other future products are expected to be entirely newplants that can serve as sentinels of environmental contamination, for example, and collections of microorganisms that can produce chemical compounds efficiently. Engineered microbes, plants, and insects designed to live in the environment with little or no human management are likely to be more common. With few exceptions, products such as these have not yet been evaluated by the current regulatory system.

Current staffing levels, expertise, and resources available at EPA, FDA, USDA and other agencies may not be sufficient to address the expected scope and scale of future biotechnology products, the report says. It is critical that the agencies involved in regulation develop and maintain scientific capabilities, tools, and expertise in key evolving areas. Examples of such areas include understanding relationships between intended genetic changes and an organism's observable traits, the unintended effects of genetic changes on target and non-target organisms, predicting and monitoring ecosystem responses, and quantifying the economic and social costs and benefits of biotechnologies.

To respond to the expected increase and diversity of products, the agencies should develop risk-analysis approaches tailored to the familiarity of products and the complexity of their uses, the report says. For biotechnology products that are similar to products already in use, established risk-analysis methods can be applied or modified, and a more expedited process could be used. For products that have less-familiar characteristics or more complex risk pathways, new risk-analysis methods may need to be developed. Regulatory agencies should build their capacity to rapidly determine the type of risk-analysis approaches most appropriate for new products entering the regulatory system.

EPA, FDA, and USDA should identify products that could serve as pilot projects to develop new approaches to assess risks and benefits and to inform regulatory decisions, the report says. Pilot projects could also be used by the agencies to evaluate future products as they move from laboratory scale, to field- or prototype-scale, to full-scale operation.

One challenge regulators will face is finding jurisdiction under existing statutes to regulate the diverse range of anticipated biotech products, the report says. The current collection of statutes and regulations that provide the basis for agencies' oversight, known as the Coordinated Framework for Regulation of Biotechnology, appears to have considerable flexibility to cover a wide range of biotechnology products, but in some cases the agencies' jurisdiction has been defined in ways that could leave gaps or overlaps in regulatory oversight. At times, FDA, EPA, and USDA may need to make use of the flexibility under their statutes to minimize gaps in jurisdiction.

Even when statutes do allow agencies to regulate products, the current statutes may not adequately equip regulators with the tools to regulate the products effectively, the committee said. For example, the statutes may not empower regulators to require product sponsors to share in the burden of generating information about product safety, and may place the burden of proof on regulators to demonstrate that a product is unsafe before they can take action to protect the public. This implies that adequate federal support for research will be crucial to protect consumer and occupational safety and the environment.

Biotechnology products on the horizon are likely to generate substantial public debate, the report notes. Many members of society have concerns over the safety and ethics of various biotechnologies, while others see prospects for biotechnology addressing social or environmental problems. The U.S. regulatory system will need to achieve a balance among competing interests, risks, and benefits when considering how to manage development and use of new biotech products.

In addition, more research may be needed to develop methods for governance systems that integrate ethical, cultural, and social implications into risk assessments in ways that are meaningful. This may not be feasible or even justified for all new biotechnology productssuch as products with which there is already familiarity or products that will not be released into the environment. For example, genetically engineered organisms used in the research laboratory to develop new chemical synthesis methods are not likely to require the same level of public dialogue as products that have more uncertainty associated with them, such as organisms with gene drives, which enhance organisms' ability to pass certain genetic traits on to their offspring.

Overall, the federal government should develop a strategy that scans the horizon for new biotechnology products, identifying and prioritizing those products that are less familiar or that present a need for more complex risk analysis, the report says. The federal government should also work to establish appropriate federal funding levels for sustained, multiyear research to develop the necessary advances in regulatory science. To this end, the National Science Foundation, the U.S. Department of Defense, the U.S. Department of Energy, the National Institutes of Standards and Technology, and other agencies that fund biotechnology research should increase their investments in regulatory science.

Explore further: Mosquitoes, Zika and biotech regulation

Provided by: National Academies of Sciences, Engineering, and Medicine

Some chemicals added to furniture, electronics and numerous other goods to prevent fires may have unintended developmental consequences for young children, according to a pilot study released today.

Confidence in doctors, therapists and nursing staff leads to an improvement in subjectively perceived complaints, satisfaction and quality of life in patients. This is the conclusion of a meta-analysis by psychologists at ...

A new study finds that caffeine may protect the lungs from damage caused by prolonged oxygen therapy, such as oxygen supplementation given to premature babies. The article is the first of its kind to study the positive effects ...

For the most part, adjusting our clocks an hour aheadas we will do this weekendcomes as good news: it is a welcome change from the long, dark winter.

It's oft-repeated but true: exercise keeps you healthy. It boosts your immune system, keeps the mind sharp, helps you sleep, maintains your muscle tone, and extends your healthy lifespan. Researchers have long suspected that ...

Research at Oregon State University suggests that photographs of your food are good for a lot more than just entertaining your friends on social media - those pictures might help improve your health and also national nutrition ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the original post here:
Federal agencies need to prepare for greater quantity, range of ... - Medical Xpress

Nasdaq Composite Index Approaches Record High as … – Economic Calendar

Posted on by

The Nasdaq Composite Index rose Wednesday, buoyed by broad advances at biotechnology and IT companies, after the Federal Reserve decided to raise interest rates for the second time in three meetings.

The technology-heavy index rose 0.7% to 5,900.05, its fifth advance in the last six sessions. The benchmark index settled just below all-time highs.

With the gain, the Nasdaq has returned nearly 10% for the year, outpacing the S&P 500 Index and Dow Jones Industrial Average.

A total of 2,009 companies listed on the Nasdaq reported gains, versus 888 that finished lower and 229 that went unchanged. A total of 166 companies reported new highs, versus 47 that set new lows.

Health stocks listed on the S&P 500 rose more than 1%, with pharmaceuticals, biotechnology and life sciences leading the rally. Information technology also advanced 0.6% as a sector.

Advertising

The Nasdaq Biotechnology Index rose 1.5% to 3,162.82.

The Federal Reserve raised its benchmark interest rate by a quarter point to 1% in a move that was widely anticipated by the markets. Policymakers continue to expect three rate increases this year, putting the central bank on course for two additional adjustments in 2017.

In terms of upcoming releases, the U.S. Labor Department will report on initial jobless claims on Thursday. Separately, the Commerce Department will report on housing starts and building permits. The Philadelphia Fed will also report on regional manufacturing conditions in the early morning.

Read more:
Nasdaq Composite Index Approaches Record High as ... - Economic Calendar

Thursday’s Biotech Insights: Aurinia Pharmaceuticals Inc (AUPH), Puma Biotechnology Inc (PBYI) – Smarter Analyst

Posted on by

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares skyrocketed over 65% this morning, after the drug maker announced top-line results from its AURA-LV Phase IIb study with voclosporin (VCS) in patients with lupus nephritis (LN) that showed at 48 weeks, the study met its complete remission (CR) and partial remission (PR) endpoints.

FBR analyst Vernon T. Bernardino commented, We are impressed with the results, as CRs and PRs at 48 weeks exceeded CRs and PRs at 24 weeks, with one exception. As a reminder, each study arm included standard of care mycophenolate mofetil (MMF) as background therapy and a forced steroid taper. There were no unexpected safety signals or deaths observed in VCS-treated patients. Thus, in addition to strong efficacy, VCS appears to allow safe steroid sparing. We think the results are robust and bode well for a successful Phase III trial, which could make VCS the first approved therapy for LN.

As of this writing,the 4 analysts polled by TipRanks (in the past 6months) rate Aurinia stock a Buy. With a return potential of 39%, the stocks consensus target price stands at $8.50.

Puma Biotechnology Inc (NASDAQ:PBYI) shares lost one-quarter of their value today, after competitor Roche announced positive top-line results from the highly anticipated APHINITY trial,which explores usefulness of Perjeta in adjuvant breast cancer. Recall, Puma has US/EU regulatory applications under review for neratinib in the extended adjuvant setting based on positive Phase 3 ExteNET data.

J.P Morgan Cory Kasimov commented, Todays PR is expectedly light on details, so well have to wait for ASCO to get the full picture. In our view, the future of neratinib in this indication largely rests on the nuances of the data, namely: 1) the magnitude of benefit, 2) the subgroups that drive this benefit (HR+ and/or HR-), and 3) details of the safety profile. The ultimate impact on Puma remains to be seen, but this outcome has obviously taken the near-term best-case scenario off the table. Our prevailing expectation was that on positive APHINITY results, PBYI shares could initially lose roughly 1/3 of their value. That said, investor feedback weve been getting has suggested that this potential dip could provide an opportunity ahead of the ASCO details as well as a number of pending neratinib data points in 1H17.

Out of the 8 analysts polled by TipRanks (in the past 12 months), 6 rate Puma Biotechnology stock a Buy, while 2 rate the stock a Hold. With a return potential of 180%, the stocks consensus target price stands at $79.

See the article here:
Thursday's Biotech Insights: Aurinia Pharmaceuticals Inc (AUPH), Puma Biotechnology Inc (PBYI) - Smarter Analyst

Why Puma Biotechnology Inc. Got Hammered Today – Motley Fool

Posted on by

What happened

Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed "Aphinity."

Image source: Getty Images.

In Roche's trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy, and then took Perjeta and Herceptin, or just Herceptin, for an additional year. Roche didn't release the full data from the clinical trial, but it did say the triple combination reduced the risk of recurrence of invasive disease or death compared to Herceptin and chemotherapy alone.

The potential to establish a new standard of care where patients take Herceptin and Perjeta for a year could be problematic for Puma Biotechnology because its drug candidate, neratinib, was tested after just Herceptin use, the current standard of care.

Without any data, doctors will likely wonder whether neratinib helps patients that have received Herceptin and Perjeta. And the relapse rate for patients on the current standard of care is already quite low; if adding Perjeta decreases it further, doctors and their patients may decide taking another drug after that isn't worth it, especially given neratinib's side-effect profile.

Investors will have to wait for the full data from Aphinity -- perhaps at the American Society of Clinical Oncology meeting in June -- to know how much better Herceptin plus Perjeta is than Herceptin alone, and how that might affect neratinib's sales, assuming it's approved later this year.

Brian Orelliand The Motley Fool have no positions in any of the stocks mentioned. The Motley Fool has adisclosure policy.

More here:
Why Puma Biotechnology Inc. Got Hammered Today - Motley Fool

WATCH: Helping farmers through agricultural biotechnology – Rappler – Rappler

Posted on by

The UP Genetic Researchers and Agricultural Innovators Society strives to uphold awareness on the ways, means, and science behind agricultural biotechnology to help students and farmers alike

Published 6:59 AM, March 06, 2017

Updated 9:19 AM, March 06, 2017

MANILA, Philippines How can agricultural biotechnology help and serve farmers and students alike?

These students from the University of the Philippines Genetic Researchers and Agricultural Innovators Society or UP GRAINS found a way.

We think its important to promote biotechnology because its one of the most advanced fields of science and we think it is also neglected in the Philippines," founding Vice-President of UP Grains Kohlin Lallaban said.

UP GRAINS, which was formed in 2014 in UP Los Baos, is an academic organization that promotes agricultural biotechnology. The group helps farmers make a living. Its programs allow students from Batangas, Laguna, and Camarines Norte provinces learn about techniques in biotechnology and how they can apply these to their research.

They bring experts and professors from different universities in Laguna and Batangas to communities, teaching farmers how to grow their crops better.

The student organization has touched lives through its programs which include academic tutorials (Chem 40: Basic Organic Chemistry Tutorials), educational discussions (AgriBioTalk Series), inter-high school information drives (Lakbay-Bioteknolohiya Workshops), farmer-oriented extension programs (Ugnayan Series), interactive advocacy campaigns (#EveryButilCounts, Free Demo Shirt Printings), and even a nationwide junior research conference (Project BT).

There was this one time that we did an extension activity in Laguna. We pushed the farmers to establish an irrigation system for their farm. Right now, theyre producing almost 40% more of cavans of rice than they were able to produce before, Lallaban shared.

One of the greatest ironies in the Philippines is that food producers like farmers and fishermen are the most vulnerable to hunger. UP GRAINS wants to change this situation in rural communities. By change, they mean continuous innovation for a better future, according to Lallaban.

"We think that the biggest lesson that our organization learned from our immersions is that there are bigger things than us, there are bigger things that we have to do, there are bigger things that we have to think about and that there is no better time to do that than now." Rappler.com

UP GRAINS is a partner organization of Rappler's civic engagement arm MovePH. For more information on how you can help or be part of UP GRAINS, check out their stories on X. Know more about our other organization partners:

Do you want your organization to be part of MovePH's X Network? Email us at move.ph@rappler.com!

At Rappler, we believe there are many freedoms: to speak, to choose, to love, or just to be. #InspireCourage is our campaign to encourage people to speak up, engage in issues, and continue fighting for the change they want to see. Be part of the conversation

See original here:
WATCH: Helping farmers through agricultural biotechnology - Rappler - Rappler

Aphinity All But Confirms Puma’s Worst Nightmare – Seeking Alpha

Posted on by

With Roche (OTCQX:RHHBY) today saying its Aphinity trial of Perjeta delivered a positive result biotech investors have seen a key binary event of 2017. True, nothing has been revealed about Perjetas numerical benefit, but for Pumas (NYSE:PBYI) neratinib things could hardly have been expected to be worse.

The likely timeline now has full Aphinity data being released at Asco perhaps at the meetings plenary session, given Aphinitys potential to be practice changing in breast cancer treatment. Puma will cling to neratinibs vanishing potential in a patient subgroup, but the US FDA should now have ammunition to deal neratinib a fatal blow after a post-Asco adcom.

Perjeta and neratinib were set on this collision course after neratinib was delayed by a tweak to the statistical analysis of its Extenet trial. Extenet and Aphinity both concern extended adjuvant treatment of Her2-positive breast cancer patients who have initially been given Roches Herceptin.

Extended adjuvant

True, they have slightly different designs, though they both measure efficacy in terms of invasive disease-free survival (iDFS).

Aphinity gave patients Perjeta plus Herceptin for a year versus Herceptin alone; Extenet had neratinib being given alone after a years Herceptin, presumably on the grounds that the Hera trial had shown two years Herceptin to give no added benefit over one.

Either way, the positive hit in Aphinity could render neratinib irrelevant, since the benefit the Puma project has shown in Extenet is tiny and questionable owing to vast amounts of patients being censored (Event Roche has Aphinity for Perjeta trial success, but not Puma, January 5, 2017).

Moreover, neratinib treatment has been associated with serious diarrhea, notwithstanding Pumas attempts to mitigate this with Imodium. Roche investors today breathed a sigh of relief, sending the stock up 6%, while Puma crashed 20% in early trade.

How good?

Investors will now want to know just how strong a benefit Perjeta has shown in Aphinity. A theoretical risk is that given the trials size nearly 5,000 patients strong statistical significance is possible from a marginal numerical benefit.

However, Roche previously revealed that it was keen to get a positive result into Asco; the deadline for submitting late-breaking abstracts for the meeting is March 16. It is virtually inconceivable that Roche would hold back borderline data for submission as an Asco late-breaker.

UBS analysts put it more strongly, earlier stating that, based on various analytical models, Statistical geekery tells us what the worst possible good result looks like; and it ain't bad ... statistical significance likely means clinical significance.

Changing practice

Beyond Aphinity being potentially practice changing, its positive readout has important repercussions for Roche, which now has a good defence against Herceptin biosimilars. Payers could see Perjeta and Herceptin bundled together at an attractive price as preferable to negotiating separately with Roche and biosimilar makers.

Neratinib has an FDA action date of July 20, with an advisory panel expected to be convened before that. Importantly, this will come after the potential Asco presentation; true, Perjeta will not yet have the Aphinity data on its label, but a practice-changing trial would be difficult for the panel and FDA to ignore.

Pumas last hope will be to cling to neratinibs purported benefit in a post hoc subset of hormone receptor-positive patients, but whether reviewers buy this is anyones guess. Meanwhile, it has been hit by an EU knockback, with regulators there telling it to restrict neratinibs filing to patients initiating treatment within a year of completing Herceptin.

More fireworks should be expected at the US adcom, particularly over uneven Extenet patient censoring and other data analyses; in its annual filing with the SEC, for instance, Puma revealed that only 60% of the patients in Extenet had been assessed for Her2 status a major red flag since Her2-positive is the target population.

And then there is the diarrhea side effect an even more serious problem if in Perjeta patients have an efficacious and relatively safer alternative. For Puma the proverbial just hit the fan.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Go here to see the original:
Aphinity All But Confirms Puma's Worst Nightmare - Seeking Alpha

CBDual Biotechnology Corp. Announces the Completion of their … – Yahoo Finance

Posted on by

LOS ANGELES, CA / ACCESSWIRE / March 2, 2017 / CBDual Biotechnology Corp. ("CBDUAL") announced today the completion of the company's new clinical trial center in Southern California.

CBDual's new facility provides patients with easy access to participate in clinical trials of new medical cannabis medications, therapies, and products. CBDual will develop protocols to improve patient safety and data integrity in clinical research trials in compliance with the HIPAA.

The first scheduled trial will study the medicinal and therapeutic effects of CBD on oral health. The study anticipates between 1,000-2,000 patients and will test the effects of different CBD based mouthwashes and toothpastes.

CBDual has recently entered into a cross licensing agreement with Cavitation Technologies, Inc (OTCQB: CVAT; Berlin: WTC). This agreement covers intellectual property involving the application of technology and patented processes to produce high quality pharmaceutical grade cannabis materials with increased bio-availability and increased shelf life.

Dr. Greg Rubin, CEO of CBDual Biotechnology Corp., previously commented, "The improvement of consumer and medical products require the development of the best quality and utilization of the most innovative technologies in order to achieve ultimate results. The impact of the new clinical research brings us one step closer to introducing our new products to the US markets."

Recent breakthroughs in Cannabinoid (CBD) therapies and orally administered products prompt strong forecast for 2017. The Hemp Business Journal estimated that the CBD market will emerge as a $2.1 billion market in consumer sales by 2020. That represents a 700% increase from 2016. According to the National Institute on Drug Abuse, a number of studies have shown that CBD is a non-psychoactive cannabinoid and has a wide range of medical benefits, such as anti- inflammatory and anti-oxidant and many other health related benefits.

About CBDual Biotechnology Corp

CBDual Biotechnology is a privately held; US based Biotechnology Company with a proprietary technology for enhanced oral delivery of bioactive cannabinoids. This technology promotes good gums health and overall dental health due to higher effectiveness of the delivery methodology. Company was founded in 2016 and is headquartered in California with its R&D capability in Israel and Ukraine..

Website: http://www.cbdual.com/

About Cavitation Technologies, Inc.

Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algae oil extraction, alcoholic beverage enhancement, water treatment and cannabidiol processing. As an add-on to its existing neutralization systems, the company's patented Nano Reactor allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield.

Website: http://www.ctinanotech.com/ Follow us on Twitter: https://twitter.com/ctinanotech Like us on Facebook: https://www.facebook.com/ctinanotech

Forward Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the anticipated installation and the timing of the installation, our intent to continue to focus on research and development, marketing and sales of our unique technology, our belief that our company is positioned for accelerated growth and the expected efforts to be made to enhance our shareholder's value. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company's control. Actual results could differ materially from these forward looking statements as a result of a variety of factors including, among others, the state of the economy, the competitive environment and our ability to perform the installation as anticipated and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties there can be no assurances that the forward looking statements contained in this press release will in fact transpire or prove to be accurate. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Read More

Cavitation Technologies, Inc.

Contact:

Investor Relations Jessica Steidinger Jessica@ctinanotech.com Phone (818) 718-0905

SOURCE: CBDual Biotechnology Corp.

Continued here:
CBDual Biotechnology Corp. Announces the Completion of their ... - Yahoo Finance

Biotechnology Research Review Market by Top Brands, Trends and Demand 2018 to 2023 – Fusion Science Academy

Posted on by

In 2029, the Basmati Rice market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Basmati Rice market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Basmati Rice market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Basmati Rice market research study, 2018 is considered as the base year, and 2019-2029 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @https://www.mrrse.com/sample/12019?source=atm

Global Basmati Rice market report on the basis of market players

The report examines each Basmati Rice market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Basmati Rice market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Companies Mentioned in the Report

McCormick & Co. Inc., LT Foods Ltd., The Hain Celestial Group Inc., Estraco Kft., East End Foods, The Rice n Spice Intl Ltd., KRBL Ltd., Amira Nature Foods Ltd., Mars Inc., and REI Agro Ltd. are the leading companies functional in the global market for basmati rice.

Report available at a discounted price exclusively!!! Offer ends today!!!

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/12019?source=atm

The Basmati Rice market report answers the following queries:

The Basmati Rice market report provides the below-mentioned information:

Buy This Report @ https://www.mrrse.com/checkout/12019?source=atm

Research Methodology of Basmati Rice Market Report

The global Basmati Rice market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Basmati Rice market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Basmati Rice market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Read this article:
Biotechnology Research Review Market by Top Brands, Trends and Demand 2018 to 2023 - Fusion Science Academy

How Does Seelos Therapeutics Inc (SEEL) Stock Compare to Other Stocks in Biotechnology? – InvestorsObserver

Posted on by

Seelos Therapeutics Inc (SEEL) is near the middle in its industry group according to InvestorsObserver. SEEL gets an overall rating of 46. That means it scores higher than 46 percent of stocks. Seelos Therapeutics Inc gets a 48 rank in the Biotechnology industry. Biotechnology is number 29 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 46 means the stock is more attractive than 46 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Seelos Therapeutics Inc (SEEL) stock is trading at $1.02 as of 10:03 AM on Tuesday, Feb 25, an increase of $0.01, or 1.09% from the previous closing price of $1.01. The stock has traded between $1.01 and $1.06 so far today. Volume today is less active than usual. So far 57,301 shares have traded compared to average volume of 907,898 shares.

To screen for more stocks like SEEL click here.

Originally posted here:
How Does Seelos Therapeutics Inc (SEEL) Stock Compare to Other Stocks in Biotechnology? - InvestorsObserver

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform – BioSpace

Posted on by

CAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by Biotechnology Value Fund (BVF) and Redmile Group with participation from Wellington Management Company, Bain Capital Life Sciences, funds managed by Janus Henderson Investors and BlackRock, Rock Springs Capital and a large US-based, healthcare-focused fund. Existing investors also participated in the round.

Kymera also received a strategic investment from The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) directed toward advancing the company's work to treat blood-based cancers.

"We are very excited to be joined by a top-tier group of investors as we continue on our path to become a fully integrated biotech company," said Nello Mainolfi, PhD, co-founder, President and CEO of Kymera Therapeutics. "We are well capitalized to advance up to three programs to the clinic by next year, while we continue to enhance our best-in-class platform to unlock new biology and invent new medicines."

Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics.

Kymera's lead program targets IRAK4, a protein known to play a significant role in inflammation mediated by toll-like and IL-1 receptors. Kymera is planning to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine targeted oncology indications. The company is also developing novel protein degrader therapies to target STAT3, an un-drugged oncogenic transcription factor as well as a driver of inflammation and fibrosis, in a range of cancers and chronic diseases.

"Targeted protein degradation is one of the most promising new therapeutic modalities, with the potential to transform medicine as we know it. Kymera is leading the way with an incredible team, a sophisticated drug discovery platform and important new protein degrader therapies designed to address the most elusive drug targets" said Bruce Booth, DPhil, co-founder, Chairman of the Board of Kymera Therapeutics and partner at Atlas Venture.

About Kymera Therapeutics

Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. For more information visit, http://www.kymeratx.com.

About Pegasus

Pegasus is Kymera Therapeutics' proprietary protein degradation platform, created by its team of experienced drug hunters to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases. The platform consists of informatics driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities, and degradation tools.

About The Leukemia & Lymphoma Society and Therapy Acceleration Program (TAP)

The Leukemia & Lymphoma Society (LLS) is a global leader in the fight against cancer. The LLS mission: cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS TAP is a strategic initiative that builds business alliances and collaborations with biotechnology companies and academic researchers to identify potential breakthrough therapies with the potential to change the standard of care. LLS TAP funds late stage pre-clinical studies, and proof of concept or registrational clinical trials to help advance these more quickly along the drug development and approval pathway. To learn more, visit http://www.LLS.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/kymera-therapeutics-announces-102-million-series-c-financing-to-advance-its-protein-degrader-pipeline-and-platform-301021994.html

SOURCE Kymera Therapeutics Inc.

See the article here:
Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform - BioSpace

Biotechnology – Monsanto Africa

Posted on by

Home > Biotechnology

Print This Page

Biotechnology is the use of living things to make or change products.

Many people see the science of biotechnology as a new and even controversial discovery. But biotechnology the genetic enhancement of agricultural products may be one of the oldest human activities. For thousands of years, from the time human communities began to settle, cultivate crops and farm the land, humans have manipulated the genetic nature of the crops and animals they raise through breeding. Breeding has been done to improve yields, enhance taste and extend growing seasons. All major crop plants, which provide 90 percent of the globe's food and energy intake, have been extensively manipulated, hybridized, inter-bred and modified over the millennia by countless generations of farmers intent on producing crops in the most efficient ways.

Modern agricultural biotechnology merely takes these breeding enhancements a step further, going directly to the plants DNA to make these enhancements more precise and easier to control. Crops resulting from modern agricultural biotechnology, which have been safely planted for more than ten years on over a billion acres.

Modern biotechnology has allowed scientists to develop a better understanding of the function, structure and evolution of plants and now, through gene technology, enabled scientists to switch off genes or copy them and move them between species.

In the case of agriculture, genes coding for specific traits are combined with existing varieties and hybrids to produce crop plants that are capable of performing even better. Good examples of these are insect protected cotton and maize, and herbicide resistant crops such as soya, maize and cotton. This technology also permits the combination of such traits into a single crop plant. In this way varieties and hybrids which are both herbicide and insect resistant are possible.

Given increasing demand for food, feed and fuel, agricultural biotechnology provides a way for farmers to produce more grain on the same amount of land, using fewer inputs. Ultimately, this technology helps farming become more sustainable. For farmers, biotech crops can reduce cost by raising yield, improving protection from insects and disease, or increasing tolerance to heat, drought and other stress. Value-added biotech traits can provide consumer benefits such as increased protein or oil, improved fatty-acid balance or carbohydrate enhancements.

The DNA (deoxyribonucleic acid) from different organisms is essentially the same simply a set of instructions that directs cells to make the proteins that are the basis of life. Whether the DNA is from a microorganism, a plant, an animal or a human, it is made from the same materials.

Throughout the years, researchers have discovered how to transfer a specific piece of DNA from one organism to another. The first step in transferring DNA is to "cut" or remove a gene segment from a chain of DNA using enzyme "scissors.

The researcher then uses the "scissors" to cut an opening in the recipient DNA where the gene is to be inserted. Because the cut ends of both the gene segment and the recipient DNA are chemically "sticky," they attach to each other, forming a chain of DNA that now contains the new gene. To complete the process, researchers use another enzyme to paste or secure the new gene in place.

Monsanto scientists pioneered the application of this technique for use in plants. Subsequent decades of research have allowed Monsanto specialists to apply their knowledge of genetics to use these biotechnology techniques to improve large-acre crops such as maize, soybeans and cotton. Our researchers work carefully to ensure that, except for the addition of a beneficial trait, improved crops are the same as current crops.

Current population growth is already straining the earth's resources. According to the U.S. Census Bureaus latest projections, the population will increase to 9 billion by 2042, up 50 percent from 1999.

Agricultural biotechnology is one important part of sustainable development, helping farmers do more with less. For example, biotech crops can increase yields without requiring any additional farmland, saving valuable rain forests and animal habitats. Other innovations can reduce or eliminate reliance on pesticides and herbicides that may contribute to environmental degradation. Still others can preserve precious soil and water resources, one day even allowing plants to thrive in times of drought, heat and poor soil quality.

An additional benefit of agricultural biotechnology is the increased adoption of conservation tillage by farmers. Conservation tillage methods leave crop mulch covering the ground between growing seasons, providing a protective cover that holds soil in place, minimizes runoff and dramatically decreases erosion.

Most experts agree that plant biotechnology is safe and effective. Working to implement new agricultural technology and the infrastructure required to meet future food needs will improve the quality of life for people worldwide for years to come.

View original post here:
Biotechnology - Monsanto Africa